Intrinsiqq

Hologic Inc (HOLX) Quality Score

HOLX
Quality24

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Revenue Growth
0/100
-4.0%

Below 2%, essentially flat

Cash Flow Growth
0/100
-15.6%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
100/100
-11.0%

Shrinking >2%, active buybacks

Margin Trend
0/100
-16.2pp

Contracted >2pp, margin pressure

Capital Structure
95/100
$156M

Net debt/FCF of 0.1x, easily serviceable

2022
$2.34B
$2.82B
2023
$2.72B
$2.82B
2024
$2.33B
$2.66B
2025
$2.20B
$2.63B
TTM
$2.36B
$2.52B
Return on Capital
40/100
8.0%

8–10%, clearing the bar

Customize WeightsPremiumUpgrade

SourceQuality score computed from the 10-Q filed 23 Jan 2026, covering the period ending 27 Dec 2025, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.

Fiscal year ends Sep. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Related stocks: X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Spot a number that looks wrong?

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.